Zhang Jiao, Zhuo Zhenjian, Li Wenya, Zhu Jinhong, He Jing, Su Jinsong
Department of Pediatric Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China.
School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong 999077, China.
Aging (Albany NY). 2018 Oct 25;10(10):2944-2953. doi: 10.18632/aging.101601.
Neuroblastoma is a common pediatric extra-cranial tumor of the sympathetic nervous system. XRCC1 is a scaffold protein that participates in DNA single-strand break repair by complexing with other proteins. gene polymorphisms are being increasingly explored in cancer epidemiology studies. However, the contribution of gene polymorphisms to neuroblastoma risk remains unclarified. Herein, we conducted a case-control study with 393 neuroblastoma patients and 812 controls to explore the association of gene polymorphisms (rs1799782 G>A, rs25487 C>T, rs25489 C>T and rs915927 T>C) with neuroblastoma risk. Results showed that none of the studied polymorphisms was associated with neuroblastoma risk. However, individuals with 2 risk genotypes seemed to be at significantly higher risk for neuroblastoma compared with those without risk genotype (adjusted odds ratio=1.69; 95% confidence interval=1.06-2.69). Stratified analysis revealed that the rs25489 CT/TT was strongly associated with reduced risk of neuroblastoma in the children ≤ 18 months of age and subgroup with clinical stage I+II+4s diseases, compared with CC genotypes. We also identified an increased neuroblastoma risk for carrier of 2-3 risk genotypes among children ≤ 18 months of age and subgroup with clinical stage I+II+4s. More evidence of the association between gene polymorphisms and neuroblastoma risk is needed.
神经母细胞瘤是一种常见的小儿颅外交感神经系统肿瘤。XRCC1是一种支架蛋白,通过与其他蛋白质复合参与DNA单链断裂修复。基因多态性在癌症流行病学研究中越来越受到关注。然而,基因多态性对神经母细胞瘤风险的影响仍不明确。在此,我们进行了一项病例对照研究,纳入393例神经母细胞瘤患者和812例对照,以探讨基因多态性(rs1799782 G>A、rs25487 C>T、rs25489 C>T和rs915927 T>C)与神经母细胞瘤风险的关联。结果显示,所研究的多态性均与神经母细胞瘤风险无关。然而,与无风险基因型的个体相比,具有2种风险基因型的个体患神经母细胞瘤的风险似乎显著更高(调整后的优势比=1.69;95%置信区间=1.06-2.69)。分层分析显示,与CC基因型相比,rs25489 CT/TT基因型与18个月及以下儿童以及临床分期为I+II+4s疾病的亚组中神经母细胞瘤风险降低密切相关。我们还发现,18个月及以下儿童以及临床分期为I+II+4s的亚组中,携带2-3种风险基因型的个体患神经母细胞瘤的风险增加。基因多态性与神经母细胞瘤风险之间的关联还需要更多证据。